August 9, 2019

Dear Colleagues,

The RI has commissioned thought leaders across the institute to embark on a step-wise evaluation of the current status of all Core facilities, and opportunities for updates or even new Cores that may better serve the needs of CHOP faculty. Review teams for each Core consists of CHOP-based PIs and nationally recognized expert external consultants.

Over the last 6 months, the NAP Core underwent a careful review and the recommendation of the Committee, with approval from the CSO team, was to phase out the NAP Core and phase in a Next gen sequencing facility. The NAP Core will officially close on September 30, 2019, and will no longer be accepting orders for Sanger sequencing as of September 15, 2019. Note that Sanger sequencing is available at Penn, and many local PIs may take advantage of the services of GeneWiz and other vendors for their needs. Additionally, for labs that use the Core for oligonucleotide orders, those orders may be placed directly with the vendor. Eric Rappaport, NAP Core Director, will be happy to address your questions on oligo orders, Sanger sequencing vendors, access to the self-service PCR machines, or other concerns as we transition to the newer services. The Agilent Bioanalyzer will remain as a stand-alone service, and there will be no disruption to access to the PCR machines for the time being. These two services will be reassessed once the Next gen sequencing facility is up and running.

Effective Monday, September 16th, The Nucleic Acid and PCR Core Facility (NAPCORE) will no longer be accepting samples for Sanger sequencing.  Alternatives for sample submission include the University of Pennsylvania Genomics Analysis Core Facility as well as several commercial providers listed below.  We will negotiate with these vendors to obtain preferential pricing for CHOP investigators

We want to take this opportunity to thank Eric and his excellent staff for all their hard work and dedication through the years. From custom oligonucleotide synthesis many years ago, and the development of PCR methods, the core has helped numerous CHOP investigators advance their science. Their impact to the RI mission is to be commended.

Bryan Wolf, MD, PhD, Chief Scientific Officer
Beverly Davidson, PhD, Chief Scientific Strategy Officer
Harry Ischiropoulos, PhD, Scientific Director, Research Core Services